National Institute for Health and Clinical Excellence (NICE)
NICE publishes first rapid COVID-19 guidelines
New guidelines cover the management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.
NICE has published its first 3 rapid guidelines on the care of people with suspected and confirmed COVID-19, and in patients without COVID-19.
These guidelines have been developed to maximise patient safety whilst making the best use of NHS resources and protecting staff from infection. The guideline has been developed using the interim process and methods for developing rapid guidelines on COVID-19 and recommendations are based on evidence and expert opinion.
COVID-19 rapid guideline: critical care
The guideline on critical care says that all patients on admission to hospital, irrespective of COVID-19 status, should continue to be assessed for frailty using a recognised frailty score (for example, the Clinical Frailty Scale [CFS]).
It also says the risks and benefits and likely outcomes should be discussed with patients, carers or advocates and families using decision support tools (where available) so that they can make informed decisions about their treatment wherever possible.
For patients with confirmed COVID-19, the guideline says decisions about admission to critical care should be made on the basis of medical benefit, taking into account the likelihood that the person will recover to an outcome that is acceptable to them and within a period of time consistent with the diagnosis.
COVID-19 rapid guideline: delivery of systemic anticancer treatments
The rapid guideline on the delivery of systemic anticancer treatments says that where decisions need to be made about prioritising patients for treatment, these need to take into account the level of immunosuppression associated with individual treatments and cancer types, and any other patient-specific risk factors. They should also balance the risk from cancer not being treated optimally versus the risk of becoming seriously ill if they contract COVID-19 because of immunosuppression.
Where changes need to be made to usual care because of system pressures, the guideline says consideration should be given to delivering treatment in different and less immunosuppressive regimens, different locations or via another route of administration.
COVID-19 rapid guideline: dialysis service delivery
The guideline on dialysis says that patients with suspected COVID-19 should be assessed to see whether dialysis could be delayed until their COVID-19 status is known. It also recommends that that outpatient transport services should get patients to their dialysis as scheduled to avoid their condition deteriorating, It should also be ensured that appropriate transport services are available by finding out what current transport providers are prepared to provide, and whether there are alternative providers if the current providers will not transport patients infected with COVID-19.
Further guidelines will be announced in due course but are likely to include: symptom management; patients receiving radiotherapy; and patients with rheumatoid arthritis. NICE will publish new guidelines each week until the full set has been completed, based on the priorities for patients and the NHS.
The guidelines are being produced in collaboration with NHS England/Improvement and a cross-specialty clinical group, supported by the specialist societies and Royal Colleges. NICE will make the guidelines accessible on its website so that health systems around the world can see the approach the UK is taking.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Commonly used treatments for chronic pain can do more harm than good and should not be used, says NICE in draft guidance04/08/2020 11:15:00
A number of commonly used drug treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE said in its draft clinical guideline published yesterday (3 August 2020) on the assessment and management of chronic pain in over 16s.
New combination treatment for patients with advanced kidney cancer31/07/2020 13:10:00
Adults with advanced renal cell carcinoma can now be offered avelumab with axitinib as a first line treatment option on the Cancer Drugs Fund (CDF), NICE has said in final draft guidance.
NICE publishes new COVID-19 rapid guideline on arranging planned care in hospitals and diagnostic services28/07/2020 09:15:00
NICE yesterday (27 July 2020) published a guideline on the arrangements the NHS should put in place for patients needing elective surgery and other planned treatments and procedures (including diagnostics and imaging) during the COVID-19 pandemic.
NICE signs agreement with Colombia’s Institute of Health Technology Assessment to forge closer working ties10/07/2020 14:05:00
Research and knowledge sharing key to collaborative working approach agreed the two agencies
NICE’s strategy on sustainability: current progress and next steps10/07/2020 09:15:00
Fizzah Ali, NICE clinical fellow, outlines the key steps towards a sustainability strategy at NICE.
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced06/07/2020 13:43:00
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
Cancer patients to benefit from new histology independent treatment26/06/2020 16:15:00
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
Steam treatment recommended for men with an enlarged prostate25/06/2020 16:15:00
Minimally invasive procedure involves injecting steam to destroy excess prostate tissue.
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis25/06/2020 13:43:00
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).